| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| "Everyone dies, so you might as well have fun!" Attitudes of Dutch youths about their health lifestyle |
0 |
0 |
0 |
11 |
1 |
1 |
1 |
82 |
| A Discrete Choice Experiment to Obtain a Tariff for Valuing Informal Care Situations Measured with the CarerQol Instrument |
0 |
0 |
0 |
1 |
3 |
3 |
5 |
16 |
| A Framework for Including Family Health Spillovers in Economic Evaluation |
0 |
0 |
1 |
1 |
0 |
1 |
6 |
10 |
| A QALY loss is a QALY loss is a QALY loss: a note on independence of loss aversion from health states |
0 |
0 |
0 |
2 |
1 |
1 |
3 |
44 |
| A cost‐effectiveness threshold based on the marginal returns of cardiovascular hospital spending |
0 |
0 |
0 |
4 |
3 |
3 |
7 |
47 |
| A new prevention paradox: The trade-off between reducing incentives for risk selection and increasing the incentives for prevention for health insurers |
0 |
0 |
0 |
11 |
1 |
1 |
1 |
52 |
| A short note on measuring subjective life expectancy: survival probabilities versus point estimates |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
27 |
| A test of independence of discounting from quality of life |
0 |
0 |
0 |
7 |
1 |
3 |
6 |
93 |
| Acceptability of less than perfect health states |
0 |
0 |
0 |
4 |
1 |
2 |
2 |
40 |
| Acceptable health and priority weighting: Discussing a reference-level approach using sufficientarian reasoning |
0 |
0 |
0 |
4 |
1 |
3 |
4 |
29 |
| Adaptation in life satisfaction and self-assessed health to disability - Evidence from the UK |
1 |
1 |
1 |
1 |
2 |
4 |
5 |
12 |
| Altruistic Preferences in Time Tradeoff |
0 |
0 |
0 |
1 |
0 |
2 |
5 |
16 |
| An elicitation of utility for quality of life under prospect theory |
0 |
0 |
0 |
10 |
1 |
1 |
3 |
79 |
| Are some QALYs more equal than others? |
0 |
0 |
0 |
5 |
1 |
1 |
2 |
48 |
| Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall |
0 |
0 |
0 |
2 |
3 |
3 |
6 |
53 |
| Benefits beyond health in the willingness to pay for a quality-adjusted life-year |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Braving the waves: exploring capability well-being patterns in seven European countries during the COVID-19 pandemic |
0 |
0 |
2 |
2 |
0 |
0 |
3 |
4 |
| Broadening the application of health technology assessment in the Netherlands: a worthwhile destination but not an easy ride? |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
6 |
| Can we fix it? Yes we can! But what? A new test of procedural invariance in TTO‐measurement |
0 |
0 |
0 |
18 |
0 |
1 |
4 |
175 |
| Care for a break? An investigation of informal caregivers' attitudes toward respite care using Q-methodology |
0 |
0 |
1 |
26 |
2 |
2 |
3 |
117 |
| Caring for and caring about: Disentangling the caregiver effect and the family effect |
0 |
0 |
0 |
52 |
2 |
2 |
7 |
351 |
| Comparing WTP Values of Different Types of QALY Gain Elicited from the General Public |
0 |
0 |
0 |
6 |
1 |
1 |
2 |
41 |
| Competition among health care providers: helpful or harmful? |
0 |
0 |
0 |
11 |
0 |
0 |
3 |
48 |
| Correction: Braving the waves: exploring capability well-being patterns in seven European countries during the COVID-19 pandemic |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
4 |
| Corrigendum to "Decision makers' views on health care objectives and budget constraints: results from a pilot study" [Health Policy 70 (2004) 33-48] |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
27 |
| Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature |
0 |
0 |
0 |
6 |
0 |
0 |
0 |
43 |
| Coverage with evidence development for medical devices in Europe: Can practice meet theory? |
0 |
0 |
1 |
1 |
0 |
0 |
2 |
6 |
| Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges |
0 |
0 |
0 |
2 |
1 |
1 |
2 |
16 |
| DERIVING TIME DISCOUNTING CORRECTION FACTORS FOR TTO TARIFFS |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
25 |
| Decision makers' views on health care objectives and budget constraints: results from a pilot study |
0 |
0 |
0 |
29 |
0 |
0 |
3 |
119 |
| Development and Content Validation of the 10-item Well-being Instrument (WiX) for use in Economic Evaluation Studies |
0 |
0 |
0 |
0 |
0 |
2 |
4 |
13 |
| Development of Population Tariffs for the CarerQol Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving |
0 |
0 |
0 |
2 |
1 |
1 |
1 |
26 |
| Did the COVID-19 pandemic change the willingness to pay for an early warning system for infectious diseases in Europe? |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
4 |
| Did the health of the Dutch population improve between 2001 and 2008? Investigating age- and gender-specific trends in quality of life |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
23 |
| Discounting and decision making in the economic evaluation of health‐care technologies |
1 |
1 |
4 |
73 |
1 |
2 |
10 |
292 |
| Discounting future health gains: an empirical enquiry into the influence of growing life expectancy |
0 |
0 |
2 |
31 |
1 |
1 |
6 |
161 |
| Discounting in Economic Evaluations |
0 |
0 |
4 |
5 |
3 |
4 |
12 |
62 |
| Discounting in decision making: the consistency argument revisited empirically |
0 |
0 |
0 |
12 |
0 |
1 |
1 |
73 |
| Discounting in economic evaluations: stepping forward towards optimal decision rules |
0 |
0 |
0 |
51 |
0 |
0 |
0 |
229 |
| Distributional consequences of including survivor costs in economic evaluations |
0 |
0 |
0 |
0 |
0 |
2 |
3 |
6 |
| Do Productivity Costs Matter? |
0 |
0 |
1 |
14 |
1 |
2 |
3 |
92 |
| Do people desire to be healthier than other people? A short note on positional concerns for health |
0 |
0 |
0 |
11 |
0 |
0 |
0 |
67 |
| Does the EQ-5D Reflect Lost Earnings? |
0 |
0 |
1 |
7 |
1 |
1 |
4 |
98 |
| Economic evaluation and the postponement of health care costs |
0 |
0 |
0 |
14 |
1 |
1 |
2 |
66 |
| Economic valuation of informal care |
0 |
0 |
1 |
13 |
2 |
2 |
4 |
57 |
| Economic valuation of informal care: Lessons from the application of the opportunity costs and proxy good methods |
0 |
0 |
0 |
23 |
1 |
1 |
2 |
105 |
| Economic valuation of informal care: The conjoint measurement method applied to informal caregiving |
0 |
0 |
0 |
16 |
0 |
0 |
1 |
86 |
| Economic valuation of informal care: the contingent valuation method applied to informal caregiving |
0 |
0 |
1 |
83 |
2 |
2 |
5 |
306 |
| Estimating a Preference-Based Value Set for the Mental Health Quality of Life Questionnaire (MHQoL) |
0 |
0 |
0 |
1 |
1 |
2 |
5 |
11 |
| Estimating an anchored utility tariff for the well-being of older people measure (WOOP) for the Netherlands |
0 |
0 |
0 |
0 |
2 |
2 |
4 |
12 |
| Estimating an exchange‐rate between care‐related and health‐related quality of life outcomes for economic evaluation: An application of the wellbeing valuation method |
0 |
0 |
0 |
5 |
1 |
1 |
3 |
19 |
| Estimating sign-dependent societal preferences for quality of life |
0 |
0 |
0 |
5 |
1 |
2 |
4 |
59 |
| Estimating the costs of non-medical consumption in life-years gained for economic evaluations |
0 |
0 |
0 |
0 |
3 |
4 |
5 |
11 |
| Estimating the monetary value of health and capability well-being applying the well-being valuation approach |
0 |
0 |
0 |
7 |
0 |
1 |
1 |
44 |
| Examining the Effect of Depicting a Patient Affected by a Negative Reimbursement Decision in Healthcare on Public Disagreement with the Decision |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
2 |
| Expectations regarding length and health related quality of life: Some empirical findings |
0 |
0 |
0 |
16 |
2 |
2 |
2 |
94 |
| From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare |
0 |
0 |
0 |
2 |
0 |
0 |
1 |
22 |
| From representing views to representativeness of views: Illustrating a new (Q2S) approach in the context of health care priority setting in nine European countries |
0 |
0 |
1 |
4 |
0 |
0 |
2 |
28 |
| Future Costs in Cost-Effectiveness Analyses: Past, Present, Future |
0 |
0 |
0 |
2 |
1 |
2 |
4 |
28 |
| Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost‐Effectiveness Analysis |
0 |
0 |
0 |
7 |
0 |
0 |
4 |
45 |
| Future costs in economic evaluation: A comment on Lee |
0 |
0 |
0 |
11 |
0 |
0 |
2 |
66 |
| Future unrelated medical costs need to be considered in cost effectiveness analysis |
0 |
0 |
0 |
3 |
0 |
2 |
3 |
58 |
| GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation |
0 |
0 |
0 |
29 |
1 |
2 |
6 |
182 |
| Give me a break!: Informal caregiver attitudes towards respite care |
0 |
0 |
0 |
41 |
0 |
1 |
2 |
264 |
| Handbook of Health Economics |
0 |
0 |
1 |
347 |
1 |
3 |
6 |
940 |
| Happy with Your Capabilities? Valuing ICECAP-O and ICECAP-A States Based on Experienced Utility Using Subjective Well-Being Data |
0 |
0 |
0 |
0 |
1 |
2 |
3 |
8 |
| Health Effects in Significant Others |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
| Health losses at the end of life: a Bayesian mixed beta regression approach |
0 |
0 |
0 |
6 |
0 |
0 |
2 |
36 |
| How does participating in a deliberative citizens panel on healthcare priority setting influence the views of participants? |
0 |
1 |
1 |
1 |
1 |
2 |
4 |
11 |
| How to Estimate Productivity Costs in Economic Evaluations |
0 |
0 |
1 |
31 |
0 |
1 |
4 |
103 |
| How to Include Informal Care in Economic Evaluations |
0 |
0 |
0 |
13 |
0 |
0 |
2 |
50 |
| How to value safety in economic evaluations in health care? A review of applications in different sectors |
0 |
0 |
0 |
0 |
2 |
4 |
4 |
20 |
| Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries |
0 |
0 |
0 |
0 |
0 |
1 |
3 |
5 |
| In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era |
0 |
0 |
0 |
9 |
3 |
4 |
6 |
44 |
| In search of a preferred preference elicitation method: A test of the internal consistency of choice and matching tasks |
0 |
0 |
1 |
11 |
2 |
4 |
6 |
81 |
| Increasing tobacco taxes: A cheap tool to increase public health |
0 |
0 |
1 |
42 |
3 |
3 |
5 |
158 |
| Influence of waiting time on cost-effectiveness |
0 |
0 |
3 |
19 |
4 |
4 |
8 |
100 |
| Is silence golden? A test of the incorporation of the effects of ill‐health on income and leisure in health state valuations |
0 |
0 |
0 |
6 |
0 |
0 |
0 |
78 |
| Jumping the Queue:Willingness to Pay for Faster Access to COVID-19 Vaccines in Seven European Countries |
0 |
0 |
0 |
0 |
2 |
3 |
3 |
3 |
| LEAD TIME TTO: LEADING TO BETTER HEALTH STATE VALUATIONS? |
0 |
0 |
0 |
1 |
1 |
1 |
2 |
54 |
| Life satisfaction: The role of domain‐specific reference points |
0 |
0 |
0 |
3 |
1 |
1 |
4 |
19 |
| Lifetime Medical Costs of Obesity: Prevention No Cure for Increasing Health Expenditure |
0 |
0 |
0 |
1 |
2 |
3 |
3 |
12 |
| Living up to expectations: Experimental tests of subjective life expectancy as reference point in time trade-off and standard gamble |
0 |
0 |
0 |
3 |
3 |
4 |
6 |
41 |
| Looking back and moving forward: On the application of proportional shortfall in healthcare priority setting in the Netherlands |
0 |
0 |
0 |
5 |
0 |
2 |
3 |
18 |
| Measuring Care-Related Quality of Life of Caregivers for Use in Economic Evaluations: CarerQol Tariffs for Australia, Germany, Sweden, UK, and US |
0 |
0 |
0 |
0 |
1 |
2 |
6 |
24 |
| Measuring Health Spillover Effects in Caregivers of Children with Autism Spectrum Disorder: A Comparison of the EQ-5D-3L and SF-6D |
0 |
0 |
0 |
1 |
1 |
2 |
3 |
16 |
| Measuring Health Spillovers for Economic Evaluation: A Case Study in Meningitis |
0 |
0 |
0 |
0 |
2 |
2 |
7 |
18 |
| Measuring the affordability of medicines: Importance and challenges |
0 |
0 |
0 |
7 |
1 |
2 |
5 |
37 |
| Moving Forward with Taking a Societal Perspective: A Themed Issue on Productivity Costs, Consumption Costs and Informal Care Costs |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
| Multiplier Effects and Compensation Mechanisms for Inclusion in Health Economic Evaluation: A Systematic Review |
0 |
0 |
0 |
0 |
2 |
3 |
3 |
5 |
| New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year |
0 |
0 |
0 |
0 |
1 |
1 |
3 |
26 |
| Obtaining preference scores for an abbreviated self-completion version of the Teen-Addiction Severity Index (ASC T-ASI) to value therapy outcomes of systemic family interventions: a discrete choice experiment |
0 |
0 |
0 |
0 |
1 |
2 |
3 |
10 |
| On spillovers in economic evaluations: definition, mapping review and research agenda |
0 |
0 |
1 |
1 |
1 |
1 |
6 |
7 |
| On the economic foundations of CEA. Ladies and gentlemen, take your positions! |
0 |
0 |
0 |
98 |
0 |
1 |
2 |
226 |
| Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19 |
0 |
0 |
0 |
39 |
3 |
3 |
4 |
161 |
| Patient and general public preferences for health states: A call to reconsider current guidelines |
0 |
0 |
0 |
16 |
1 |
1 |
3 |
86 |
| Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al |
0 |
0 |
0 |
2 |
0 |
0 |
1 |
25 |
| Piecing the jigsaw puzzle of adolescent happiness |
0 |
0 |
0 |
21 |
1 |
2 |
5 |
150 |
| Practice guidelines based on clinical and economic evidence |
0 |
0 |
0 |
3 |
0 |
0 |
1 |
27 |
| Predicting productivity based on EQ-5D: an explorative study |
0 |
0 |
2 |
9 |
3 |
3 |
7 |
39 |
| Preference-Based Health-Related Quality-of-Life Outcomes in Children with Autism Spectrum Disorders |
0 |
0 |
0 |
9 |
1 |
1 |
1 |
125 |
| Preferences of citizens in Peru for school opening during a public-health crisis: A participatory value evaluation study |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
| Presentation and validation of the Abbreviated Self Completion Teen-Addiction Severity Index (ASC T-ASI): A preference-based measure for use in health-economic evaluations |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
10 |
| Priority care for employees: A blessing in disguise? |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
151 |
| Private clinics for employees as a Dutch solution for waiting lists: economic and legal arguments |
0 |
0 |
0 |
4 |
0 |
1 |
1 |
39 |
| Process utility from providing informal care: the benefit of caring |
0 |
0 |
3 |
37 |
1 |
1 |
5 |
144 |
| Production Losses due to Absenteeism and Presenteeism: The Influence of Compensation Mechanisms and Multiplier Effects |
0 |
0 |
0 |
0 |
1 |
1 |
5 |
10 |
| Productivity Costs Measurement Through Quality of Life? A Response to the Recommendation of the Washington Panel |
0 |
0 |
0 |
7 |
0 |
0 |
1 |
247 |
| Productivity cost calculations in health economic evaluations: Correcting for compensation mechanisms and multiplier effects |
0 |
0 |
0 |
6 |
0 |
1 |
3 |
37 |
| Productivity costs before and after absence from work: as important as common? |
0 |
0 |
2 |
33 |
1 |
1 |
4 |
121 |
| Productivity costs in cost‐effectiveness analysis: numerator or denominator: a further discussion |
0 |
0 |
1 |
10 |
0 |
0 |
5 |
199 |
| Productivity losses without absence: measurement validation and empirical evidence |
0 |
0 |
0 |
39 |
1 |
1 |
2 |
122 |
| Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic |
0 |
0 |
0 |
6 |
1 |
1 |
5 |
37 |
| Prospect theory in the health domain: A quantitative assessment |
0 |
0 |
0 |
17 |
1 |
1 |
3 |
113 |
| Public preferences for policies promoting a healthy diet: a discrete choice experiment |
0 |
0 |
0 |
0 |
0 |
1 |
4 |
12 |
| Public views on principles for health care priority setting: Findings of a European cross-country study using Q methodology |
0 |
0 |
0 |
10 |
1 |
4 |
4 |
113 |
| Putting your money where your mouth is: Parents' valuation of good oral health of their children |
0 |
0 |
0 |
2 |
3 |
3 |
4 |
48 |
| QALYs without bias? Nonparametric correction of time trade‐off and standard gamble weights based on prospect theory |
0 |
0 |
1 |
1 |
1 |
1 |
4 |
40 |
| Quality of Life and Time to Death |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
| Quality of life instruments for economic evaluations in health and social care for older people: A systematic review |
1 |
1 |
2 |
15 |
3 |
3 |
6 |
75 |
| Quantifying the Impoverishing Effects of Purchasing Medicines: A Cross-Country Comparison of the Affordability of Medicines in the Developing World |
0 |
0 |
0 |
1 |
0 |
3 |
5 |
23 |
| Rationalising rationing: economic and other considerations in the debate about funding of Viagra |
0 |
0 |
0 |
16 |
1 |
1 |
1 |
63 |
| Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
3 |
| Reference‐dependent age weighting of quality‐adjusted life years |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
3 |
| Respite care--An explorative study of demand and use in Dutch informal caregivers |
0 |
0 |
1 |
13 |
2 |
2 |
3 |
69 |
| Severity-Adjusted Probability of Being Cost Effective |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
26 |
| Should I stay or should I go? Waiting lists and cross-border care in the Netherlands |
0 |
0 |
0 |
39 |
0 |
0 |
2 |
104 |
| Some pain, no gain: experiences with the no-claim rebate in the Dutch health care system |
0 |
0 |
0 |
24 |
1 |
1 |
1 |
108 |
| Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists |
0 |
0 |
0 |
0 |
1 |
2 |
2 |
2 |
| Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
32 |
| The Impact of Hospital Payment Schemes on Healthcare and Mortality: Evidence from Hospital Payment Reforms in OECD Countries |
0 |
0 |
0 |
11 |
1 |
4 |
5 |
46 |
| The Inclusion of Spillover Effects in Economic Evaluations: Not an Optional Extra |
0 |
0 |
0 |
5 |
0 |
0 |
3 |
27 |
| The Incorporation of Income and Leisure in Health State Valuations When the Measure Is Silent: An Empirical Inquiry into the Sound of Silence |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
3 |
| The Monetary Value of Informal Care: Obtaining Pure Time Valuations Using a Discrete Choice Experiment |
0 |
0 |
0 |
1 |
2 |
4 |
6 |
21 |
| The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice |
0 |
0 |
0 |
0 |
0 |
1 |
4 |
7 |
| The Value of a QALY: Individual Willingness to Pay for Health Gains Under Risk |
0 |
0 |
2 |
24 |
1 |
2 |
6 |
86 |
| The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys |
0 |
0 |
0 |
3 |
0 |
0 |
2 |
38 |
| The correction of TTO-scores for utility curvature using a risk-free utility elicitation method |
0 |
0 |
0 |
27 |
2 |
2 |
5 |
124 |
| The desire for support and respite care: preferences of Dutch informal caregivers |
0 |
0 |
0 |
14 |
0 |
0 |
3 |
63 |
| The efficiency frontier approach to economic evaluation: will it help German policy making? |
0 |
0 |
0 |
30 |
0 |
0 |
0 |
84 |
| The evaluation of lifestyle interventions in the Netherlands |
0 |
0 |
0 |
8 |
0 |
0 |
1 |
50 |
| The influence of subjective expectations about length and quality of life on time trade‐off answers |
0 |
0 |
0 |
17 |
1 |
1 |
3 |
99 |
| The influence of subjective life expectancy on health state valuations using a 10 year TTO |
0 |
0 |
0 |
21 |
0 |
1 |
8 |
209 |
| The missing link: on the line between C and E |
0 |
0 |
0 |
12 |
0 |
0 |
2 |
55 |
| The relative value of carer and patient quality of life: A person trade-off (PTO) study |
0 |
0 |
0 |
0 |
1 |
2 |
3 |
4 |
| The role of budget impact and its relationship with cost-effectiveness in reimbursement decisions on health technologies in the Netherlands |
1 |
1 |
1 |
1 |
1 |
1 |
3 |
5 |
| The value of health—Empirical issues when estimating the monetary value of a quality‐adjusted life year based on well‐being data |
0 |
1 |
1 |
11 |
1 |
3 |
3 |
40 |
| The value of informal care–a further investigation of the feasibility of contingent valuation in informal caregivers |
0 |
0 |
0 |
55 |
1 |
2 |
3 |
195 |
| The way that you do it? An elaborate test of procedural invariance of TTO, using a choice-based design |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
37 |
| Trust me; I know what I am doing investigating the effect of choice list elicitation and domain-relevant training on preference reversals in decision making for others |
0 |
0 |
0 |
1 |
1 |
1 |
4 |
27 |
| United but divided: Policy responses and people’s perceptions in the EU during the COVID-19 outbreak |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
16 |
| Unpaid work in health economic evaluations |
0 |
0 |
0 |
12 |
1 |
3 |
6 |
52 |
| Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal |
0 |
0 |
0 |
1 |
0 |
0 |
2 |
27 |
| Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a ‘perfect’ cost–utility ratio |
0 |
0 |
1 |
57 |
1 |
1 |
2 |
316 |
| VALUING QALY GAINS BY APPLYING A SOCIETAL PERSPECTIVE |
2 |
3 |
3 |
31 |
2 |
3 |
5 |
130 |
| Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment |
0 |
0 |
0 |
6 |
1 |
1 |
2 |
35 |
| Views of older people in the Netherlands on wellbeing: A Q-methodology study |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
14 |
| Welfarism vs. extra-welfarism |
0 |
0 |
1 |
200 |
2 |
2 |
4 |
789 |
| Well-being of Older People (WOOP): Quantitative validation of a new outcome measure for use in economic evaluations |
0 |
0 |
0 |
10 |
0 |
1 |
4 |
70 |
| What Constitutes Well-being? Five Views Among Adult People from the Netherlands on what is Important for a Good Life |
0 |
0 |
0 |
0 |
9 |
9 |
11 |
16 |
| What is it going to be, TTO or SG? A direct test of the validity of health state valuation |
0 |
0 |
0 |
12 |
1 |
2 |
6 |
61 |
| What should we know about the person behind a TTO? |
0 |
0 |
0 |
2 |
0 |
0 |
1 |
23 |
| What works better for preference elicitation among older people? Cognitive burden of discrete choice experiment and case 2 best-worst scaling in an online setting |
0 |
1 |
1 |
3 |
0 |
1 |
1 |
18 |
| When Time is Not on Your Side |
0 |
0 |
0 |
20 |
1 |
1 |
3 |
337 |
| When is it too expensive? Cost-effectiveness thresholds and health care decision-making |
0 |
0 |
0 |
6 |
1 |
2 |
4 |
77 |
| When time is more than money: The allocation of time between work and leisure in HIV-infected patients |
0 |
0 |
0 |
14 |
0 |
0 |
0 |
93 |
| Willingness to pay for an early warning system for infectious diseases |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
37 |
| Willingness to pay for health gains from an international integrated early warning system for infectious disease outbreaks |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
4 |
| Willingness to pay for quality and length of life gains in end of life patients of different ages |
0 |
0 |
0 |
3 |
2 |
2 |
3 |
9 |
| With a little help from an anchor: Discussion and evidence of anchoring effects in contingent valuation |
0 |
0 |
0 |
63 |
0 |
0 |
4 |
243 |
| YOUR RIGHT ARM FOR A PUBLICATION IN AER? |
0 |
0 |
2 |
16 |
3 |
3 |
15 |
129 |
| Total Journal Articles |
6 |
10 |
54 |
2,411 |
154 |
236 |
552 |
12,780 |
LogEc is hosted by the
Örebro University School of Business.